Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A

Haemophilia

Volumn 12, Issue 4, 2006, Pages 448-451

  Franchini, Massimo ^a   Girelli, D ^b   Olivieri, O ^b   Castaman, G ^c   Lippi, G ^b   Poli, G ^b   Salvagno, G L ^b   Tagariello, G ^d   Giuffrida, A ^a   De Gironcoli, M ^a   Morfini, M ^e   Berntorp, E ^f   Gandini, G ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UO di Pediatria   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bleeding; Inhibitors; Mild haemophilia A

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR;

ARTICLE; BLOOD; BRAIN HEMORRHAGE; CASE REPORT; DRUG ANTAGONISM; EXON; FATALITY; GENETICS; HEMOPHILIA A; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MUTATION; RISK FACTOR;

BLOOD COAGULATION FACTOR INHIBITORS; CEREBRAL HEMORRHAGE; EXONS; FACTOR VIII; FATAL OUTCOME; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; MUTATION; RISK FACTORS;

EID: 33846669469     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01297.x     Document Type: Article

References (26)

1. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thromb Haemost 1992; 67: 600-2.
2. Rizza CR, Spooner RJ. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) 1983; 286: 929-33.
3. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-8.
4. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36.
5. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
6. Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
7. Robbins D, Kulkarni R, Gera R, Scott-Emuakpor AB, Bosma K, Penner JA. Successful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol 2001; 68: 184-8.
8. Leebeek FW, Kappers-Klunne MC, Jie KS. Effective and safe use of recombinant factor VIIa (NovoSeven) in elderly mild haemophilia A patients with high-titre antibodies against factor VIII. Haemophilia 2004; 10: 250-3.
9. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
10. Jacquemin M, De Maeyer M, D'Oiron R, Lavend'Homme R, Peerlinck K, Saint-Remy JM. Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost 2003; 1: 456-63.
11. Santagostino E, Gringeri A, Tagliavacca L, Mannucci PM. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin. Thromb Haemost 1995; 74: 619-21.
12. Fijnvandraat K, Turenhout EA, van den Brink EN et al. The missense mutation Arg593 -> Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997; 89: 4371-7.
13. Thompson AR, Murphy ME, Liu M et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 1997; 90: 1902-10.
14. Suzuki H, Shima M, Arai M et al. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost 1997; 77: 862-7.
15. van den Brink EN, Timmermans SM, Turenhout EA et al. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593->Cys substitution. Thromb Haemost 1999; 81: 723-6.
16. Peerlinck K, Jacquemin MG, Arnout J et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 1999; 93: 2267-73.
17. Jacquemin M, Lavend'homme R, Benhida A et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96: 958-965.
18. Liu ML, Shen BW, Nakaya S et al. Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
19. Vlot AJ, Wittebol S, Strengers PF et al. Factor VIII inhibitor in a patient with mild haemophilia A and an Asn618-Ser mutation responsive to immune tolerance induction and cyclophosphamide. Br J Haematol 2002; 117: 136-40.
20. d'Oiron R, Lavergne JM, Lavend'homme R et al. Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development. Blood 2004; 103: 155-7.
21. Fernandez-Lopez O, Garcia-Lozano JR, Nunez-Vazquez R, Perez-Garrido R, Nunez-Roldan A. The spectrum of mutations in Southern Spanish patients with hemophilia A and identification of 28 novel mutations. Haematologica 2005; 90: 707-10.
22. Jacquemin M, Vantomme V, Buhot C et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. Blood 2003; 101: 1351-8.
23. Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet 1993; 2: 11-17.
24. Knobe KE, Villoutreix BO, Tengborn LI, Petrini P, Ljung RC. Factor VIII inhibitors in two families with mild haemophilia A: structural analysis of the mutations. Haemostasis 2000; 30: 268-79.
25. Ivaskevicius V, Jurgutis R, Rost S et al. Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data. Br J Haematol 2001; 112: 1062-1070.
26. Cutler JA, Mitchell MJ, Smith MP, Savidge GF. The identification and classification of 41 novel mutations in the factor VIII gene (F8C). Hum Mutat 2002; 19: 274-8.